Cargando…
An all-virtual clinical trial to assess a heart failure drug
The CHIEF-HF trial investigators employed a novel all-virtual study design to show that canagliflozin significantly reduces symptom burden in patients with heart failure.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929242/ https://www.ncbi.nlm.nih.gov/pubmed/35301453 http://dx.doi.org/10.1038/s41569-022-00691-z |